Literature DB >> 34183766

Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols.

Mary M Taj1, Anthony V Moorman2, Lina Hamadeh2, Arnaud Petit3, Vahid Asnafi4, Fanny Alby-Laurent3, Ajay Vora5, Marc R Mansour6, Rosemary Gale6, Sylvie Chevret7, John Moppett8, André Baruchel9, Elizabeth Macintyre10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34183766     DOI： 10.1038/s41375-021-01334-x

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

1.  NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.

Authors:  E Clappier; S Collette; N Grardel; S Girard; L Suarez; G Brunie; S Kaltenbach; K Yakouben; F Mazingue; A Robert; P Boutard; D Plantaz; P Rohrlich; P van Vlierberghe; C Preudhomme; J Otten; F Speleman; N Dastugue; S Suciu; Y Benoit; Y Bertrand; H Cavé
Journal:  Leukemia       Date:  2010-09-23       Impact factor: 11.528

2.  NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.

Authors:  L Zuurbier; I Homminga; V Calvert; M L te Winkel; J G C A M Buijs-Gladdines; C Kooi; W K Smits; E Sonneveld; A J P Veerman; W A Kamps; M Horstmann; E F Petricoin; R Pieters; J P P Meijerink
Journal:  Leukemia       Date:  2010-09-23       Impact factor: 11.528

3.  Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.

Authors:  Stephen Breit; Martin Stanulla; Thomas Flohr; Martin Schrappe; Wolf-Dieter Ludwig; Gabriele Tolle; Margit Happich; Martina U Muckenthaler; Andreas E Kulozik
Journal:  Blood       Date:  2006-04-13       Impact factor: 22.113

4.  NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.

Authors:  Vahid Asnafi; Agnès Buzyn; Sandrine Le Noir; Frédéric Baleydier; Arnauld Simon; Kheira Beldjord; Oumedaly Reman; Francis Witz; Thierry Fagot; Emmanuelle Tavernier; Pascal Turlure; Thibaut Leguay; Françoise Huguet; Jean-Paul Vernant; Francis Daniel; Marie-Christine Béné; Norbert Ifrah; Xavier Thomas; Hervé Dombret; Elizabeth Macintyre
Journal:  Blood       Date:  2008-12-23       Impact factor: 22.113

5.  Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

Authors:  Ajay Vora; Nick Goulden; Rachel Wade; Chris Mitchell; Jeremy Hancock; Rachael Hough; Clare Rowntree; Sue Richards
Journal:  Lancet Oncol       Date:  2013-02-07       Impact factor: 41.316

6.  Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Arnaud Petit; Amélie Trinquand; Sylvie Chevret; Paola Ballerini; Jean-Michel Cayuela; Nathalie Grardel; Aurore Touzart; Benoit Brethon; Hélène Lapillonne; Claudine Schmitt; Sandrine Thouvenin; Gerard Michel; Claude Preudhomme; Jean Soulier; Judith Landman-Parker; Guy Leverger; Elizabeth Macintyre; André Baruchel; Vahid Asnafi
Journal:  Blood       Date:  2017-10-19       Impact factor: 22.113

7.  Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.

Authors:  Amélie Trinquand; Aline Tanguy-Schmidt; Raouf Ben Abdelali; Jérôme Lambert; Kheira Beldjord; Etienne Lengliné; Noémie De Gunzburg; Dominique Payet-Bornet; Ludovic Lhermitte; Hossein Mossafa; Véronique Lhéritier; Jonathan Bond; Françoise Huguet; Agnès Buzyn; Thibaud Leguay; Jean-Yves Cahn; Xavier Thomas; Yves Chalandon; André Delannoy; Caroline Bonmati; Sebastien Maury; Bertrand Nadel; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret; Vahid Asnafi
Journal:  J Clin Oncol       Date:  2013-10-28       Impact factor: 44.544

8.  Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.

Authors:  S Jenkinson; K Koo; M R Mansour; N Goulden; A Vora; C Mitchell; R Wade; S Richards; J Hancock; A V Moorman; D C Linch; R E Gale
Journal:  Leukemia       Date:  2012-07-03       Impact factor: 11.528

9.  Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

Authors:  Ajay Vora; Nick Goulden; Chris Mitchell; Jeremy Hancock; Rachael Hough; Clare Rowntree; Anthony V Moorman; Rachel Wade
Journal:  Lancet Oncol       Date:  2014-06-09       Impact factor: 41.316

10.  The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.

Authors:  C Kox; M Zimmermann; M Stanulla; S Leible; M Schrappe; W-D Ludwig; R Koehler; G Tolle; O R Bandapalli; S Breit; M U Muckenthaler; A E Kulozik
Journal:  Leukemia       Date:  2010-10-14       Impact factor: 11.528
View more
  1 in total

Review 1.  Understanding the Notch Signaling Pathway in Acute Myeloid Leukemia Stem Cells: From Hematopoiesis to Neoplasia.

Authors:  Daniel Láinez-González; Juana Serrano-López; Juan Manuel Alonso-Dominguez
Journal:  Cancers (Basel)       Date:  2022-03-12       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.